Treatment of Tachyarrhythmias and Bradyarrhythmias by Cardiac Sympathectomy and Permanent Ventricular Pacing

Schoonmaker, Fred W.; Carey, Thomas; Grow, John B.

doi:10.1016/s0003-4975(10)65737-2

Cited by 17 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuromodulation is emerging as a therapeutic option for patients with refractory ventricular arrhythmias and ICD shocks (5,6). Cardiac sympathetic denervation (CSD) has been shown to reduce VT inducibility and ischemia-driven ventricular arrhythmias in animal models of myocardial infarction (7,8) and decrease the burden of VT and ICD shocks in small series of patients with cardiomyopathy and recurrent VT or VT storm (9–12). However, long-term outcomes in larger patient populations and predictors of VT recurrence and ICD shocks after CSD are unknown.…”

mentioning

confidence: 99%

Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias

Vaseghi

Barwad

Corrales

et al. 2017

Journal of the American College of Cardiology

281

189

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias

Vaseghi

Barwad

Corrales

et al. 2017

Journal of the American College of Cardiology

281

189

View full text Add to dashboard Cite

show abstract

“…Since then, the benefits of this procedure have been described in other case reports. 3,25–28 The current study contains the largest series of patients in whom the intermediate and long-term benefits of CSD in the treatment of refractory ventricular arrhythmias or VT storm was evaluated. This is the first study to show that in this high-risk population, CSD demonstrated benefits that extend beyond the acute postoperative period, with a reduction in ICD shock burden of close to 90%.…”

Section: Discussionmentioning

confidence: 99%

Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: Intermediate and long-term follow-up

et al. 2014

View full text Add to dashboard Cite

BACKGROUND Left and bilateral cardiac sympathetic denervation (CSD) have been shown to reduce burden of ventricular arrhythmias acutely in a small number of patients with ventricular tachyarrhythmia (VT) storm. The effects of this procedure beyond the acute setting are unknown. OBJECTIVE The purpose of this study was to evaluate the intermediate and long-term effects of left and bilateral CSD in patients with cardiomyopathy and refractory VT or VT storm. METHODS Retrospective analysis of medical records for patients who underwent either left or bilateral CSD for VT storm or refractory VT between April 2009 and December 2012 was performed. RESULTS Forty-one patients underwent CSD (14 left CSD, 27 bilateral CSD). There was a significant reduction in the burden of implantable cardioverter-defibrillator (ICD) shocks during follow-up compared to the 12 months before the procedure. The number of ICD shocks was reduced from a mean of 19.6 ± 19 preprocedure to 2.3 ± 2.9 postprocedure (P < .001), with 90% of patients experiencing a reduction in ICD shocks. At mean follow-up of 367 ± 251 days postprocedure, survival free of ICD shock was 30% in the left CSD group and 48% in the bilateral CSD group. Shock-free survival was greater in the bilateral group than in the left CSD group (P = .04). CONCLUSION In patients with VT storm, bilateral CSD is more beneficial than left CSD. The beneficial effects of bilateral CSD extend beyond the acute postsympathectomy period, with continued freedom from ICD shocks in 48% of patients and a significant reduction in ICD shocks in 90% of patients.

show abstract

“…Multiple accounts of the benefits of CSD have emerged in patients with refractory VT and structural heart disease. (Zipes et al 1968;Nitter-Hauge & Storstein, 1973;Lloyd et al 1974;Schoonmaker et al 1975) However, with the introduction of medications targeting the sympathetic nervous system (including beta-blockers and angiotensin converting enzyme (ACE) inhibitors) that significantly improved the risk of SCD (Kober et al 1995;Hjalmarson, 1997), CSD took a secondary role. It gradually became clear that despite the best available anti-arrhythmic medications and catheter ablation techniques, approximately 30-50% of patients continue to experience recurrent arrhythmias and ICD shocks (Kuck et al 2010;Mathuria et al 2012).…”

Section: Clinical Management: Specific Interventions For Heart Failurmentioning

confidence: 99%

“…; Schoonmaker et al . ) However, with the introduction of medications targeting the sympathetic nervous system (including beta‐blockers and angiotensin converting enzyme (ACE) inhibitors) that significantly improved the risk of SCD (Kober et al . ; Hjalmarson, ), CSD took a secondary role.…”

Section: Introductionmentioning

confidence: 99%

Clinical neurocardiology defining the value of neuroscience‐based cardiovascular therapeutics

Shivkumar¹,

Ajijola²,

Anand

et al. 2016

The Journal of Physiology

262

212

View full text Add to dashboard Cite

The autonomic nervous system regulates all aspects of normal cardiac function, and is recognized to play a critical role in the pathophysiology of many cardiovascular diseases. As such, the value of neuroscience-based cardiovascular therapeutics is increasingly evident. This White Paper reviews the current state of understanding of human cardiac neuroanatomy, neurophysiology, pathophysiology in specific disease conditions, autonomic testing, risk stratification, and neuromodulatory strategies to mitigate the progression of cardiovascular diseases.

show abstract

Treatment of Tachyarrhythmias and Bradyarrhythmias by Cardiac Sympathectomy and Permanent Ventricular Pacing

Cited by 17 publications

References 33 publications

Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias

Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias

Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: Intermediate and long-term follow-up

Clinical neurocardiology defining the value of neuroscience‐based cardiovascular therapeutics

Contact Info

Product

Resources

About